Opinion

Video

Addressing Payer Coverage Challenges

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Panelists discuss how they navigate challenges with payer coverage for quadruplet regimens in multiple myeloma treatment, including strategies they employ to address insurance denials or restrictions, such as providing clinical justification, leveraging recent trial data, and collaborating with financial assistance programs to ensure patients can access optimal therapy despite potential coverage difficulties.

Video content above is prompted by the following:

  • As a provider, have you noticed any difficulties regarding payer coverage for quadruplet regimens? If so, how have you addressed these challenges?

Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
Multiple Myeloma is a cancer of plasma cells, a type of white blood cell found in bone marrow - Image credit: kamonrat | stock.adobe.com
November 12th 2024

Bispecific Antibody Receives FDA Orphan Drug Designation for the Treatment of Multiple Myeloma

Kennedy Ferruggia, Assistant Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Image Credit: © CHA - stock.adobe.com
November 6th 2024

Bone Marrow Adipocytes May Offer Early Detection of MGUS Progression to Multiple Myeloma

Alexandra Gerlach, Associate Editor
Image Credit: © Сергей Косилко - stock.adobe.com
November 1st 2024

Carfilzomib, Lenalidomide, and Dexamethasone: A Curative Approach for Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Multiple myeloma in bone marrow -- Image credit: Saiful52 | stock.adobe.com
October 24th 2024

Advances in CAR T-Cell Therapy and Bispecifics for Relapsed/Refractory Multiple Myeloma

Alana Hippensteele, Managing Editor
Team of health care professionals -- Image credit: New Africa | stock.adobe.com
October 23rd 2024

The Pharmacist’s Role on the Multiple Myeloma Care Team Can Vary Among Cancer Centers When Treating Patients With Bispecifics

Gillian McGovern, Assistant Editor